Pharmaceuticals Immunibio Initiates Study to Evaluate Combination of Anktiva and AdHER2DC Cancer Vaccine Against Endometrial Cancer Last updated: August 7, 2024 7:44 pm By bexib 0 Min Read Share SHARE The study aims to investigate Anktiva as a potential basis for future immunotherapy treatments for endometrial cancer and other cancers. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article Fedi Launches Community-Focused Bitcoin Operating System Next Article Lumen Technologies shares continue AI surge on bright cash flow outlook Reuters – Investorempires.com Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Financial institutions leverage AI to prepare for credit boom Banking Will realignment shape the future of American politics? Economy Nobel Prize in Economics for “Inclusive” Free Markets Economy 2:00PM Water Cooler 11/15/2024 | naked capitalism Economy